GEN Exclusives

More »

GEN News Highlights

More »
May 2, 2007

Diosynth Inks Deal with VGX Pharmaceuticals

  • Diosynth Biotechnology signed an agreement with VGX Pharmaceuticals for process development and production of clinical trial material for the latter’s anticancer candidate.

    VGX Pharmaceuticals says that it has developed technology using specific viral proteins that can induce selective apoptosis in rapidly dividing cancer cells, leaving normal cells unharmed. VGX-100, a recombinant viral protein r (Vpr), induces tumor cell death through apoptosis in a number of human-derived tumor tissues, including breast, prostate, and brain. Initial clinical trials will target patients with Non-Hodgkin’s lymphoma and gastric cancer.

    The development and manufacturing program that Diosynth Biotechnology will perform employs the Dowpharma Pfenex Expression Technology™, a Pseudomonas-based technology. Pfenex Expression Technology can increase yields of recombinant protein when used in biomanufacturing applications, according to Diosynth.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »